MX2024004515A - Formas cristalinas de un benzimidazol sustituido que actua como inhibidor de cdk9 y sus usos. - Google Patents

Formas cristalinas de un benzimidazol sustituido que actua como inhibidor de cdk9 y sus usos.

Info

Publication number
MX2024004515A
MX2024004515A MX2024004515A MX2024004515A MX2024004515A MX 2024004515 A MX2024004515 A MX 2024004515A MX 2024004515 A MX2024004515 A MX 2024004515A MX 2024004515 A MX2024004515 A MX 2024004515A MX 2024004515 A MX2024004515 A MX 2024004515A
Authority
MX
Mexico
Prior art keywords
crystalline forms
acting
substituted benzimidazole
cdk9 inhibitor
cdk9
Prior art date
Application number
MX2024004515A
Other languages
English (en)
Spanish (es)
Inventor
Qun Li
Huaping Zhang
Liang Lu
Ganfeng Cao
Andrew Combs
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MX2024004515A publication Critical patent/MX2024004515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/14—Adipic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004515A 2021-10-14 2022-10-14 Formas cristalinas de un benzimidazol sustituido que actua como inhibidor de cdk9 y sus usos. MX2024004515A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163255562P 2021-10-14 2021-10-14
PCT/US2022/078143 WO2023064920A1 (en) 2021-10-14 2022-10-14 Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
MX2024004515A true MX2024004515A (es) 2024-07-01

Family

ID=84272325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004515A MX2024004515A (es) 2021-10-14 2022-10-14 Formas cristalinas de un benzimidazol sustituido que actua como inhibidor de cdk9 y sus usos.

Country Status (10)

Country Link
US (1) US20250011298A1 (enExample)
EP (1) EP4416139A1 (enExample)
JP (1) JP2024539631A (enExample)
KR (1) KR20240115816A (enExample)
CN (1) CN118355006A (enExample)
AU (1) AU2022362075A1 (enExample)
CA (1) CA3234907A1 (enExample)
IL (1) IL312030A (enExample)
MX (1) MX2024004515A (enExample)
WO (1) WO2023064920A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020345950A1 (en) * 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2025189114A1 (en) 2024-03-08 2025-09-12 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020345950A1 (en) * 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals

Also Published As

Publication number Publication date
KR20240115816A (ko) 2024-07-26
CA3234907A1 (en) 2023-04-20
AU2022362075A1 (en) 2024-05-09
JP2024539631A (ja) 2024-10-29
WO2023064920A1 (en) 2023-04-20
US20250011298A1 (en) 2025-01-09
EP4416139A1 (en) 2024-08-21
CN118355006A (zh) 2024-07-16
IL312030A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
CL2022002341A1 (es) Compuestos y métodos para modular el empalme
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
DOP2019000040A (es) Compuestos de pirrolizina sustituidas y usos de los mismos
CL2018002794A1 (es) Compuestos bicíclicos
UY36781A (es) Fenoxihalogenofenilamidinas y su uso como fungicidas
CO2022012594A2 (es) Inhibidores del eif4e y sus usos
MX2020007531A (es) Aminopirrolotriazinas como inhibidores de cinasa.
NI201900075A (es) Compuesto moduladores del receptor de hidrocarburos de arilo (ahr)
CL2019001736A1 (es) Polimorfos.
CL2019001737A1 (es) Polimorfos.
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
MX2019010642A (es) Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
CL2022001456A1 (es) Tiofenocarboxamidas sustituidas y sus derivados
CR20160224A (es) Composición herbicida que comprende inhibidores ACC
CL2018002023A1 (es) Uso de moduladores de receptores de gabaa para el tratamiento de picor.
NI202000042A (es) Polimorfos
CL2022001594A1 (es) Tiofenocarboxamidas sustituidas y sus derivados
CO2020001861A2 (es) Inhibidores de ror gamma
CL2022001612A1 (es) Tieniloxazolonas y análogos
UY36628A (es) Indazolonas como moduladores de la señalización de tnf
MX2016015106A (es) Derivados de dipicolilamina y sus usos farmaceuticos.
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
CL2018003872A1 (es) Sales cristalinas del inhibidor de inmunoproteasoma de péptido epoxicetona.